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Abstract
In this thesis we propose a novel statistical natural history model and illustrate
how it can be applied to epidemiological breast cancer screening data to increase
knowledge about how breast cancers progress over time and how likely they are
to be detected by both screening and by symptoms. The model may be useful in
helping to design future individualised screening programmes for breast cancer.
In Study I a continuous tumour growth model for jointly estimating tumour
growth, time to symptomatic detection and mammography screening sensitivity
as a function of percentage mammographic density, PD, is presented. The model
is applied to data extracted from Swedish postmenopausal breast cancer cases
(the same study base is used in Studies I-III). PD is significantly associated with
screening sensitivity. Growth rates are found to have a high
individual-to-individual variability.
In Study II the continuous tumour growth model is extended to allow for
covariates in all submodels (tumour growth, symptomatic detection and
screening sensitivity). A previously described positive association between body
size and tumour size is found to be mainly caused by difficulties in symptomatic
detectability/delay in visiting health care.
In Study III we compare the statistical powers of detecting image markers
related to masking between the continuous tumour growth model and logistic
regression using interval vs. screen-detected cancer as the dependent variable.
Based on simulated data, we show that statistical power can be higher when tests
are based on the continuous tumour growth model. Using observational data, we
study an image marker of scatteredness of mammographically dense tissues in
terms of screening sensitivity. PD did not include any additional information
regarding sensitivity once SI’s role in sensitivity was accounted for.
In Study IV, using our continuous tumour growth model framework, we derive
individual (conditional) lead time distributions, based on a woman’s tumour size,
screening history and percentage mammographic density. We propose a lead time
bias correction that can be used in survival comparisons between e.g. screen-
detected and interval cases. In a simulation study, we explore the length-biased
sampling. Results showed that the sampling should be viewed in the light of the
tumour growth rate and the tumour size at which the tumour would have become
symptomatically detected in absence of screening.
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List of abbreviations and mathematical notations
AD Absolute (amount of) mammographic density
AJCC American Joint Committee on Cancer
BFGS Broyden–Fletcher–Goldfarb–Shanno (a numerical optimisation algorithm)
BI-RADS A four category (A-D) qualitative classification of mammographic density
BMI Body Mass Index
BRCA1/2 Breast Cancer Susceptibility Gene 1 or 2
CAHRES Cancer and Hormone Replacement Study
CISNET Cancer Intervention and Surveillance Modeling Network
ER Estrogen Receptor
HER2 Human Epidermal growth factor Receptor 2
HRT Hormone Replacement Therapy
L Random variable for lead time
L(·) Likelihood function
log(·) Base-e log (or the natural logarithm)
MD Mammographic density
MLE Maximum likelihood estimation
MLO Mediolateral oblique view
PD Percent mammographic density
PR Progesterone Receptor
R Random variable for inverse tumour growth rate
S(·) Mammography screening sensitivity function
SI Skewness of the intensity gradient (measure of scatteredness of MD)
RCC Regional Cancer Centre
TBA Total breast area measured in pixels on a mammogram
Tdet(·) Time in years between tumour onset and detection, in absence of screening
TNM Classification system used for staging of breast cancers
V (·) Tumour volume function
Vdet(·) Symptomatic tumour volume function
1 Introduction
To lower mortality from breast cancer, mammography screening is used with the purpose
of detecting cancers early in their disease progression, when their curability is high. The
age-based screening programmes used in today’s health care systems may, in the future,
be replaced by individualised, risk-based, screening programmes. In designing such
programmes, knowledge of the natural history of breast cancer will be useful. Screening
programmes will need to use information on which women have a high risk of getting
the disease, but can also make great use of information, at an individual level, on how
long breast cancers are likely to be present in women’s bodies before symptoms evolve
and on the sensitivity of screening.
Tumour characteristics of breast cancer cases are typically only observable at their
time points of diagnosis. Still, by adding longitudinal data on screening history, insights
about the inherently unobservable processes of cancer progression can be provided, by
analysing such data using statistical (natural history) models.
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2 Background
In 2012, around the globe, 8.2 million persons died due to cancer. Half a million of these
deaths were due to breast cancer, which accounts for 15% of the cancer deaths in women
[1]. Advancements in cancer treatment and the implementation of national screening
programmes in many countries have made many cancer types less deadly. Cancer cells
arise from mutations and lose characteristics that normal cells possess: they resist cell
death, sustain proliferative signalling and activate invasion to nearby cells/tissues. These
are three of the ten hallmarks of cancer presented by Hanahan and Weinberg [2]. Cancer
may evolve in different parts of the human body. Depending on the specific type of cancer,
how far it has progressed, the age and any possible comorbidity of the patient as well as
where in the world she or he lives, the curability of the disease differs. If cancer is left
untreated or is not curable, it may in the later stage of the disease lead to that healthy body
organs cease to function, due to loss of space and nutrition demanded by the cancer cells
[3].
2.1 Breast cancer
Breast cancer is the most commonly diagnosed cancer among women in the world and
especially high incidence rates can be seen in, for example, Northern America, Western
Europe, Oceania and Argentina, see Figure 2.1 [1]. A high incidence may be induced by
genetic predisposition, a high prevalence of environmental risk factors for breast cancer,
as well as overdiagnosis due to screening for the disease. Many of the countries in the
above mentioned regions have implemented national screening programmes [4]. The
highest age-standardised mortalities are more heterogeneously scattered over the globe
and are seen, for example, in such countries as Denmark, Ireland, Ukraine, Pakistan,
Afghanistan, some Middle-Eastern countries, Africa’s horn, Egypt, Chad, Nigeria,
Argentina and Malaysia, see Figure 2.2. In less developed countries breast cancer is the
most common cause of cancer death in women, whereas in more developed countries it
is the second most common cause, after lung cancer [1].
In the Nordic countries (Sweden, Norway, Denmark, Finland and Iceland) incidence
has steadily increased over the last decades [5]. All of these countries have implemented
nation-wide screening programmes: Sweden gradually between 1976-1997 [6], Finland
in 1987 [7], Iceland in 1987 [8], Denmark gradually between 1991-2010 [9, 10] and
Norway gradually between 1996-2005 [11]. Although incidence has increased in these
countries, rates of mortality have been decreasing gradually, see Figure 2.3. Annually
in Sweden, around 7,500 women are diagnosed with breast cancer and around 1,400 die
from the disease [12]. The relative 5-year survival has improved over the last decades,
see Figure 2.3 (note that estimates may be influenced by lead time and overdiagnosis, see
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Figure 2.1: Worldwide age-standardised incidence per 100,000 person years.
Source: GLOBOCAN [1].
Figure 2.2: Worldwide age-standardised mortality per 100,000 person years.
Source: GLOBOCAN [1].
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Figure 2.3: Above: Time trends in age-standardised incidence and mortality per
100,000 person years in the Nordic countries. Below: Time trend in 5-year age-
standardised relative breast cancer survival in Sweden. Source: NORDCAN [5].
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Section 2.2.4). The relative survival is the ratio of the observed survival in the patient
group to the expected survival in an exchangeable group of the general population (with
respect to sex, age and calendar time at the time of diagnosis) [5].
2.1.1 Disease progression
The female breast consists of adipose tissues (fat) and fibroglandular parenchyma. The
latter is a collection name of glandular elements and connective tissues (supporting
stroma) [13]. The glandular elements contain the lobules and ducts where the milk is
produced and drained into the nipple area during periods of breast-feeding [14]. The
fraction of adipose tissues to fibroglandular parenchyma varies with age, in such a way
that older women have more adipose tissues [15]. Breast composition also changes at
times of pregnancy, breast-feeding and during menopause.
The glands are the origin for most breast cancer tumours, which arise more frequently
in the ducts than the lobules [16]. Breast cancers can be invasive (invading tissues outside
the ducts or lobules) or non-invasive (staying within the gland). There are also benign
tumours consisting of cells that lack some of the characteristics of cancer cells (e.g. ability
to metastasise), but these are not called cancer. How different the cancer cells are from
normal cells is measured by the grade of the tumour. Cells with a low grade are more like
normal cells and grow slowly, cells with a high grade are less like normal cells and grow
fastly [17].
Tumour stage
Over time breast cancers progress through stages. In the local stage the cancer is a tumour
within the breast that increases in size. After some time, the cancer cells spread through
the lymph system to the lymph nodes and the cancer reaches the regional stage. In the
distant stage the cancer cells spread through the bloodstream to distant organs, e.g. the
bones, lungs, brain or liver. This is a simplistic explanation, which not all cancers follow.
For example, not all cancers may have the ability to become distant. However, when
tumour stage is mentioned in this thesis, we refer to this process.
At the clinics, the staging procedure used by physicians for choosing an appropriate
treatment, is much more detailed. The classical anatomic staging procedure, is based
on the TNM classification, in which T stands for tumour size, N stands for lymph node
metastasis and M stands for distant metastasis. The three classifiers are each given a
score, which are summarised to form a complete breast cancer stage from 0-IV (which
also includes subgroups) [18].
In the latest (8th) tumour staging guidelines, the American Joint Committee on
Cancer, AJCC, advocate the use of prognostic stages, where the breast cancers are
classified according to their predicted survival times, such that a higher stage means
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worse prognosis. This staging procedure allows for more disease heterogeneity, by the
inclusion of factors such as grade, hormone receptor positive status (ER/PR/HER2) and
multigene panels [19].
In Norway the (anatomic) stage specific 5-year relative survival, for cases diagnosed
between the years 2007-2011, was 100% for Stage I, 92% for Stage II, 76% for Stage
III and 26% for Stage IV [20]. This thesis is centered around statistical modelling of the
first component (T) in the TNM classification. In data from the Netherlands for cases
diagnosed between the years 2006-2012, 5-year relative survival was reported to be 98-
101% for T1a-T1c (diameter ≤ 2 cm), 92% for T2 (2 cm < diameter ≤ 5 cm), 81% for
T3 (diameter > 5 cm) and 59% for T4 (tumour growing into chest wall or skin) [21].
Measures of proliferation and rates of tumour progression
At the time of breast cancer diagnosis, proliferation of the cancer cells (in the primary
tumour) may be recorded, which describes how fast the tumour is growing/cancer cells
are dividing. Since proliferation may vary through the course of the disease progression,
this value only measures the growth at the time point of surgery. There are different ways
of measuring proliferation in tumours; two of these are by using the S-phase fraction or,
more common nowadays, the protein marker Ki-67.
The S-phase fraction represents the fraction of cells at flow cytometry that are in the
synthetic phase (part of cell cycle where the DNA replication occurs, before cell division
begins) [22]. Hedley et al. [23] described the methodology in 1987, based on
node-positive breast cancer. The protein marker Ki-67 was identified in 1991 by Gerdes
et al. [24] as a potential marker of cell proliferation. It has been found to be highly
expressed in proliferating tissues, but rarely seen in resting cells [25]. One downside
with the measure is that the Ki-67 expression varies in intensity throughout the cell cycle
[26], which increases measurement errors/variability. This issue is however common for
other markers of proliferation as well [27].
The expression of Ki-67 correlates with the S-phase fraction (and other measures of
proliferation) and a high S-phase fraction or Ki-67 value is a sign of poor prognosis
[23, 27]. The expert panel responsible for constructing the new AJCC tumour staging
guidelines [18], considered using measures of proliferation, but eventually decided not to
incorporate them (at least for now), because of technical issues and problems with
reproducibility [28]. Both the S-phase fraction (in a study of ~400 cases [22]) and Ki-67
(in a study of ~1800 cases [29]) have been reported to be positively correlated with
tumour size. It is however not clear whether results of the second study were affected by
the length bias (explained in Section 2.2.4).
Tumour growth/progression describes how fast the tumour is progressing over time
and the process is typically unobserved. Statistical models can be built around an
assumption of a constant or non-constant rate throughout the course of the disease, see
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Section 2.3.3. Rates of growth/progression are likely to be correlated but not equivalent
to rates/measures of proliferation, which can vary over time and across the tumour.
2.1.2 Symptomatic detectability
Breast cancer that is not detected by screening is found via symptoms. The most
common symptom is feeling a lump in the breast, but other symptoms may be swelling,
skin irritation, pain, redness and nipple discharge or retraction [30]. In a Finnish study
by Singh et al. [31], which included more than one million screening visits from the
national screening programme (both with and without a resulting cancer diagnosis). It
was found that in 25% of the recorded visits, symptoms were also recorded, either by the
woman or the radiographer. Among the visits that resulted in an invasive breast cancer
diagnosis, 36% of the women had recorded symptoms. However, most of the women
with recorded symptoms had no present breast cancer.
It has been hypothesised that symptom onset may be delayed in women with large
breasts [32–34]. In this thesis a proxy for breast size is used, called total breast area, TBA,
measured in pixels from a mammogram. In Figure 2.4 an example of two different TBA’s
are shown. All mammograms included in this thesis have been altered to e.g. enhance
local contrasts and increase the level of details. In these shown mammograms, it seems
reasonable that lumps are easier to detect in the smaller breast, but it would of course also
depend on the location of the tumour. In a study of close to 500 screen-detected breast
cancer cases, with a negative clinical breast examination one year earlier, predictors of
poor clinical breast examination sensitivity were reported to be obesity and young age
[35]. The reason for young age may however be due to the higher risk for fast-growing
tumours in younger women [36–38].
A delayed symptomatic diagnosis could be caused by both a delayed symptom onset
and a delayed visit to health care after symptoms have evolved.
2.1.3 Risk factors
Breast cancer is more common in some groups of persons than others. In Sweden a typical
breast cancer case is a middle-aged to older woman, the median age at diagnosis was 66
years in 2016 [12]. Although it is rare, breast cancer can occur already in female teenagers
and in men. The overall incidence rate of breast cancer in women increases steadily with
age. In the United Kingdom, the age-specific incidence rates per 100,000 person years
have been reported to be 30.4 and 478.3 in women between 30-34 and 85-89 years old,
respectively [39]. A natural effect of this is that incidence of breast cancer may increase
in aging populations.
There are many known risk factors for breast cancer, other than age and sex. Some
of these are listed below; the emphasis here is however kept to the variables included
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Figure 2.4: An example of a difference in total breast area, with a small
breast represented on the left mammogram and a large represented on the right
mammogram.
in Studies I-IV. These specific variables have been chosen due to their association with
tumour size (body size and breast tissue composition) [32–34, 40, 41].
Breast tissue composition
Tissues in the breast can be categorised as being adipose tissue or fibroglandular
parenchyma. The latter tissue type is often called mammographic density, MD, due to its
appearance on mammograms, while adipose tissue is called non-dense. This will be
described further in Section 2.2.1. MD is a strong risk factor for breast cancer, both in
terms of the absolute (amount of) dense tissue, AD [42], and in terms of the fraction of
dense tissue, PD [43], seen in a breast, on a mammogram. In a meta-analysis using more
than 14,000 cases a relative risk of 4.64 was estimated, comparing women with PD being
more than 75% to less than 5% [43]. A high PD has also been shown to be associated
with a larger tumour size at diagnosis [40, 41].
Body size
Higher BMI has been found to increase the breast cancer risk in postmenopausal women
[44]. The relationship in premenopausal women has been reported to be the opposite,
where the BMI at age 18 was even more predictive of breast cancer risk than the BMI at
diagnosis [45]. Taller women have been reported to have a higher risk of getting breast
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cancer [46]. Reasons behind the link between breast cancer risk and body size are
complex [32]. Women with a high BMI are also more likely to have higher amounts of
adipose tissues in the breasts, thus BMI is negatively correlated to PD [47]. Body size is
positively associated with tumour size at diagnosis [32–34, 48].
Hormone replacement therapy
The use of Hormone replacement therapy, HRT, at menopause is not included as a variable
in the models reported in the studies of this thesis. It is however worth briefly describing
something about its role in breast cancer here, because of its relation with body size and
MD. HRT users have a higher risk of getting breast cancer, which could be due to the
exogenous source of circulating hormones [49]. Usage has also been found to increase
MD [50], but there is no consistent evidence of weight gain caused by HRT [51]. It has
been found that HRT attenuates the effect of body size on breast cancer risk [52].
Other factors
The rare mutations in the BRCA1 and BRCA2 genes strongly increase the risk of breast
cancer [53]. There exists other more common mutations in other genes, but they do not
increase the breast cancer risk to the same extent. Other risk factors related to genes
are a recorded family history of breast and/or ovarian cancer, as well as ethnicity. Some
forms of previous benign breast diseases, as well as a previous breast cancer diagnosis
and high endogenous estrogen or testosterone levels also increase future risk of breast
cancer. Environmental risk factors that increase the risk are low age at menarche, high
age at first birth, low parity, low level of breast-feeding, high age at first pregnancy, high
age at menopause, high-dose radiation to chest, intake of alcohol, current use of oral
contraceptives and low physical activity [46]. Hysterectomy, bilateral ovariectomy and
mastectomy reduce future risk of breast cancer [54, 55].
A note on menopausal status
In line with the increasing age-specific incidence rates, breast cancer is more common in
postmenopausal women than in premenopausal. The causes behind the disease [44], the
types of breast cancer [56] and also the breast tissue composition [57] differ somewhat
between the groups. Studying both groups in the same analysis may thus lead to
difficulties in interpretation of results.
2.2 Mammography screening
In mammography screening low doses of X-rays are used to examine breasts and possibly
detect masses that could be cancer. Screening is carried out with the aim that breast
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cancers can be detected at an earlier time in the disease progression, when the chance
of cure is higher than at the time of symptomatic detection [58]. Some decades ago,
randomised clinical trials were performed to find evidence that women invited to regular
mammography screening had a reduced breast cancer mortality compared to women that
were not invited. Nine trials were included in a recent review (meta-analysis) by the
Independent UK panel on breast cancer screening [59]. These trials dated from 1963
to 1991 (in terms of sample size Swedish studies stood for a total weight of close to
50%). Invitation to screening was estimated to reduce mortality by 20% for women aged
50-69 years old. In reviews by the Cochrane Collaboration [60, 61], some of the clinical
trials were however criticised for having a suboptimal randomisation procedure. Based on
the (three) adequately randomised trials invitation to screening was estimated to reduce
mortality by 10%. It however remains unclear whether the effect seen in the trials is
similar in clinical settings nowadays, due to better treatments being available [59]. The
effect of attending a screening programme on mortality should be higher than the effect of
being invited. The effect of attendance is however more complex to evaluate as adherence
to screening is not a random event.
As a result of the trials, national screening guidelines and programmes have been (and
are still being) implemented in many countries across the globe. In Sweden,
recommendations are to invite women from 40 to 74 years old, with an interval of 18-24
months and 70-80% of the invited women participate in the screening programme [62].
There could be a benefit for women also in other age ranges to be screened, although
there is no documented evidence of this (clinical trials have not been performed).
Women with a genetic predisposition, a family history of the disease or a previous breast
cancer diagnosis may follow other routines.
Observational data have also been used to evaluate the impact of screening
programmes on mortality reductions. Estimates based on such data are however prone to
biases, which is the reason that clinical trials, although old, still stand for the main
evidence of the usefulness of mammography screening programmes [59]. Berry et al.
[63] presented thorough evaluations of screening in terms of breast cancer mortality in
the United States between 1975 to 2000, by summarising seven different statistical
modelling techniques performed by different research groups included in the Cancer
Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Working
Group consortium [64], see Section 2.3.4. Comparing the years 1990 to 2000, breast
cancer mortality had decreased by 24% (from 49.7 to 38 women per 100,000). The
different research groups came to the conclusion that screening stood for 28 to 65% of
the total decrease, the remainder being contributed to by adjuvant treatment (over the
years, the use of adjuvant chemotherapy and tamoxifen had been increasing) [63]. In
recent work Plevritis et al. [65] presented a similar evaluation but also incorporated
information on molecular subtypes of breast cancer.
Benefits from being invited to a mammography screening programme could also be
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measured in terms of increased survival instead of reduced mortality. This is rarely done
as results would be affected by the lead time bias (Section 2.2.4). It is however clear that,
especially at an individual level, survival time as a continuous measure includes more
information than mortality as a dichotomous measure.
Whilst the benefits of systematic screening are reduced mortality and prolonged
survival, harms can be detection of too many slow-growing cancers (i.e. cases that could
be overdiagnosed and consequently over-treated), increased anxiety, use of ionising
radiation and economical costs for health care systems [58, 59]. Research is ongoing for
evaluating and improving the balance between the benefits and harms of screening
programmes, for instance by looking at new ways of individualising screening
programmes (not just using the age of women) [66, 67].
2.2.1 Mammography screening sensitivity and mammographic density
A tool used for routine screening programmes should be able to detect the disease of
interest, i.e. it should have a high sensitivity, so that, in the case of breast cancer,
tumours/masses present at the time point of screening are not missed. Mammography is
able to detect tumours of very small sizes and it also has the ability to detect changes in
breast tissue in the form of microcalcifications, which sometimes are a sign of malignant
changes [68]. Mammograms are depicted from different views of the breast. The
mediolateral oblique (MLO) view is important as it depicts the highest fraction of breast
tissue [69]. On mammograms, tumours appear as white masses and are easily seen
against a background of fatty tissues (non-dense) which are depicted as dark areas. In
low-dense breasts, which are more common in elderly women, sensitivity is high [70].
Even though small-sized tumours can be detected at mammography, it is not, in general,
true in mammographically dense breasts. In breasts with a high MD, tumours may be
masked, since MD also appears white on mammograms. Thus, a high MD both increases
breast cancer risk and reduces mammography screening sensitivity.
One qualitative measure of MD is presented in the Breast Imaging Reporting and Data
System (BI-RADS) [71]. The measure can be used by radiologists to categorise MD into
one of four categories, for assessing risk of masking. In the latest edition from 2013 the
categories are constructed as
the breasts are almost entirely fattya)
there are scattered areas of fibroglandular densityb)
the breasts are heterogeneously dense, which may obscure small massesc)
the breasts are extremely dense, which lowers the sensitivity of mammographyd)
Other qualitative measures are the mammographic parenchymal pattern developed by
Wolfe [72] and the Tabar classifications developed by Gram et al. [73].
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Figure 2.5: An example of a difference in percentage mammographic density, with
low PD represented on the left mammogram and high PD represented on the right
mammogram.
Quantitative measures of MD are, for instance, absolute mammographic density (AD)
and percentage mammographic density (PD). The latter is a function of both the dense
and non-dense tissues seen in a breast (the fraction of dense pixels to the total number of
dense and non-dense pixels). For creating AD and PD, a threshold for pixel intensity is
used for determining whether a pixel is dense or not. Byng et al. [74] developed a semi-
automated procedure, called Cumulus, where the operator selects the threshold value for
pixel intensity on each mammogram. Li et al. [75] developed a fully automated technique,
using ImageJ, and validated it against Cumulus. Examples of (two) mammograms with
different PD values can be seen in Figure 2.5.
Previous editions of BI-RADS used PD cut-off values for constructing four categories
of MD. However, PD (and AD) does not take into account how the MD tissues are divided
in the breast in relation to the adipose tissues. Strand et al. [76] found indirect evidence
that the image feature Skewness of the intensity gradient, SI, developed by Cheddad et al.
[77] was related to mammography screening sensitivity. SI is a measure of how scattered
the dense tissues in the breast are, i.e. whether the dense tissues are grouped together in
large masses or whether they are scattered with streaks of fat between them. An example
of two mammograms with different values of SI can be seen in Figure 2.6.
There exist many more image features of MD, which mainly have been assessed for
their abilities to determine risk of breast cancer, see for example Zheng et al. [78].
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Figure 2.6: An example of a difference in skewness of the intensity gradient,
with low skewness (scattered MD) represented on the left mammogram and high
skewness (unscattered MD) represented on the right mammogram. The images are
from two women with similar percentage mammographic densities (around 20%).
2.2.2 Detection mode and screening history
Before screening programmes (and opportunistic screening) were introduced, detection
of breast cancer was done through symptom onset [79]. Nowadays breast cancer can be
detected either by symptoms, or by screening (i.e. earlier in the disease progression).
How the cancer is detected is usually called the detection mode and includes information
on, for instance, tumour characteristics. Holm et al. [80] showed that among screen
attenders, screen-detected cases had smaller tumours and less lymph nodal involvement
than symptomatic cases. Information on screening history tells whether a woman has
adhered to screening or not. The following descriptions are of types of breast cancer
cases, defined in terms of screening attendance and detection mode (based on the ideas of
the author), that can be useful to distinguish.
Screening cases
 Detected at the first (prevalent) screening round
A cancer that is detected at the first screening round may have existed for a long
time in the breast before it was detected by screening.
 Detected at the second or subsequent (incident) screening round
A cancer that is detected at a subsequent screening in a woman who attends
screening regularly is less likely to have existed for a long time in the breast.
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 First time to adhere to screening or non-regular screen attender
If a woman suddenly starts to attend screening there may be a reason for this, which
is often not recorded. Some screen-detected cases may, for instance, already have
felt symptoms.
Symptomatic cases
 Not invited to screening
A cancer detected by symptoms in a woman not invited to screening, may be a
woman too young or too old to be invited to screening. If such cases are many,
there is indirect evidence that the screening programme may need to be extended.
Such a symptomatic case can also be found in a place without resources for a
regular screening programme.
 Not attending screening or non-regular attender
In a Finnish study it was found that women who did not attend screening either
went to mammography in other places (false non-attenders), or were more
commonly depressed, anxious and socially isolated (true non-attenders) [81]. In
true non-attenders, it can be thought that tumour stage at diagnosis may be
especially high (if the women do not want to seek health care).
 Regular screen attender – Interval case
An interval case is a woman adhering to a screening programme, but with a breast
cancer symptomatically detected in the interval between two screenings.
Understanding the cause of interval cases has been subject to epidemiological
research since some of these cancers are very aggressive [80] (having progressed
from not detectable at screening to symptomatic within a short time frame).
However, this is not true for all interval cases, they can rather be divided into three
subgroups (also depicted in Figure 2.7):
– Masked interval case
A marker for this group of cases is that they have high MD and thus a
decreased mammographic screening sensitivity [82].
– Fast-growing interval case
Such cases may for instance be seen in women with a low amount of MD,
having large tumour sizes at diagnosis.
– Easy-detectable interval case
Such cases may be seen in women with a low amount of MD and small
tumour sizes. How gainful screening is for this group of women is not
known. Both of the latter groups also exist within the group of women
having a high MD.
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Figure 2.7: Three different types of interval cases. For simplicity, they are all
symptomatically detected at the same calendar time point.
2.2.3 Sojourn time, lead time and stage shift
Many interesting factors and processes of the natural history of breast cancer, arising in
mammography screening data, are unobservable. In this Section three such latent
processes (not already presented) are described.
Sojourn time
Sojourn time is the time from when a tumour is detectable at screening to when it will be
detected by symptoms. The concept arises from multi-state Markov models for cancer
screening data, see Section 2.3.2. There is however no clear definition of what the term
detectable means in relation to mammography screening sensitivity and tumour size.
The sojourn time is related to the latent processes of tumour growth/progression (how
fast the tumour increases in size/the cancer progresses through stages) and symptomatic
detectability. In Figure 2.8, two tumours, A and B, are depicted, which have the same
sojourn time, but Tumour A grows faster than Tumour B. Factors affecting the sojourn
time may be called promoters of clinical disease [83], which should not be thought of as
factors affecting only the tumour growth rate.
Lead time and stage shift
Lead time is the difference in time from when a tumour was detected in presence of
screening, to when it would have been detected by symptoms in absence of screening.
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Figure 2.8: Two cases having the same sojourn times, but different growth rates.
In general, for tumours growing with the same speed, a longer lead time gives a greater
benefit of screening. However, for a fast-growing tumour, a short lead time may still be
of great value. In Figure 2.9, the concept of lead time is depicted. Lead time is related
to processes of tumour growth, symptomatic detectability and mammography screening
sensitivity.
If we regard tumour stage as a variable that progresses over time, see Section 2.1.1, then
stage shift is the difference in tumour stage at the time for screen detection in comparison
to that when the symptomatic detection would have occurred, see Figure 2.9. Just as with
lead time, the stage shift varies between screen-detected cases. Stage shift and lead time
are correlated variables, but screening efficacy will probably depend more on the size of
the stage shift (and between which stages the shift appears) rather than the length of lead
time.
Survival time from diagnosis for screen-detected cases can be divided into three parts:
lead time, survival time that would have occurred in absence of screening and extra
survival time due to treatment being started earlier (i.e. the effect of stage shift).
2.2.4 Biases arising in mammography screening data
Comparing breast cancer specific survival, to evaluate the effect of screening, in study
populations in the presence or absence of a screening programme or with different
detection modes, may be difficult due to biases (true also for comparisons of populations
in presence of different kinds of screening programmes). However, not all survival
analyses will be biased. Whether or not there will be bias, depends on the underlying
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Figure 2.9: An illustration of lead time and stage shift.
question/comparison being addressed. Analyses concerned with the evaluation of
independent prognosticators, for data in presence of screening, are also prone to biases
[79], as are time trends in breast cancer incidence.
Lead time bias
A lead time bias occurs in comparisons where times to an event are measured from
diagnosis in presence of screening and the time point of interest is instead the time for
symptomatic detection (in absence of screening). One of the difficulties with this bias is
to conclude whether an analysis is affected or not by it, i.e. which detection time point
that is of interest to start counting time from. Evaluations of the impact of screening
programmes on breast cancer specific survival are subject to lead time bias.
Length bias
Whereas invitation to a screening programme may be randomised, detection mode among
screen attenders can never be. Specific groups of women have a higher chance of being
screen-detected, thus there exist selection biases, one of these being the length bias. The
word length comes from the length of the sojourn time, i.e. the time a tumour may be
detected by screening but not by symptoms. For a woman with breast cancer attending a
screening programme, the probability to be screen-detected increases with the length of
her sojourn time. Thus screening cases tend to have longer sojourn times than interval
cases, see Figure 2.10. In comparisons of breast cancer specific survival between groups
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Figure 2.10: An example of length-biased sampling, with four tumours having
different sojourn times. The two upper cases will be screen-detected as they were still
undetected at the time point of screening. The crosses represent times for detection.
with e.g. different detection modes, any factor, related to the sojourn time as well as
to survival (in absence of screening), will infer a length bias. Tumour growth rate is
commonly mentioned as such a factor, in the way that screen-detected cases consist of
more slow-growing cancers. MD affects the length of sojourn time through the process
of mammography screening sensitivity, but as it is probably not independently affecting
survival [84], it is not a part of the length bias. The effect of screening on survival is
however likely to be smaller in women with a high PD compared to a low, as they are
more commonly interval cases and also have larger tumour sizes at screen detection.
Invitation to and attendance of screening programmes
Another form of selection bias is related to the invitation to and attendance of screening
programmes [79]. Women attending screening may for instance be more health conscious
than the non-attenders, which potentially could cause measures of survival and incidence
to differ. Persons newly arrived to another country may not be invited immediately to
screening and may not be aware of how the health care system works.
Overdiagnosis
An overdiagnosed case is a screen-detected case, who, in absence of screening, would
not have been detected by symptoms during her remaining lifetime. An example is
depicted in Figure 2.11. Overdiagnosis is usually considered the main harm of organised
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Figure 2.11: An overdiagnosed case where death occurs before the symptomatic
detection would have taken place in absence of screening. Lead time exceeds post-
diagnostic time to death.
screening programmes, but, unfortunately it is difficult to measure/evaluate. Estimates of
the amount of overdiagnosis from breast cancer screening vary from none to quite a large
proportion of all breast cancer cases [59]. Typical cases of overdiagnosis are likely to be
non-invasive or very slow-growing tumours, or tumours detected in women with other
deadly diseases. The amount of breast cancers that are overdiagnosed is likely to be
highest in old women. In developing the Dana-Farber CISNET model (see Section
2.3.4), Lee et al. [85] estimated that, for 65-year old women, around 7% of all invasive
screen-detected cases will be overdiagnosed, whereas for 75-year old women around
13% will be overdiagnosed. Another harm of screening programmes is overtreatment,
which refers to treatment of an overdiagnosed case [86].
2.3 Natural history modelling
Knowledge about how long a tumour exists in the breast before being clinical, when it
would have been detected in absence of screening and how sensitive mammography is,
are important factors for creating or adapting screening programmes. These are all latent,
unobservable processes of breast cancer that cannot be followed directly, for, if nothing
else, ethical reasons – once an invasive tumour is detected, surgery and/or treatment will
soon begin. The processes may however be estimated by the use of a natural history
model of the disease. Data on breast cancer cases and women at risk of getting the disease,
collected in presence of screening, provide a rich source of information for unravelling the
natural history of breast cancer. One reason being that differences between breast cancer
cases in terms of e.g. tumour characteristics become larger in presence than in absence of
screening, since detection modes and screening histories vary.
Standard regression techniques are useful for their high generalisability, they may be
adapted to many different kinds of data. Related to this thesis work, they have been used
to find (positive) associations for tumour size with body size variables and PD [32, 34,
40, 41, 48]. They have also been used to find image features (e.g. PD and SI) related to
being an interval or screen-detected case [76, 80]. A common feature of these analyses are
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that the mechanisms behind the associations are not directly quantified. Natural history
modelling opens up a door for quantifying the causal pathways behind such associations.
In this Section natural history model frameworks and estimation procedures for
tumour progression (with a main emphasis on tumour size) and detection are presented.
Description of models including joint estimation of survival and tumour onset is beyond
the scope of this thesis kappa, and is thus limited.
2.3.1 Study populations used for natural history modelling
For natural history modelling, apart from randomised trials, observational data is often
used, in the form of, for example, cohort or case-only studies. Both data in absence and
presence of screening may be used, but the processes that are possible to estimate will
then differ.
In a cohort study of breast cancer a defined group of women is followed over a
specific time period and all new breast cancer diagnoses will be recorded. Such a study
has a well-defined risk set (healthy women at risk of getting breast cancer). In a study
including only breast cancer cases (e.g. Plevritis et al. [87]) the (full) population at risk
of getting cancer is not studied. However, some case-only or case-control studies may be
more detailed, including more variables for analysis than registry-based cohort studies.
For both types of studies, it is theoretically possible to estimate the natural history
processes occurring after tumour onset, such as sojourn time, tumour progression,
symptomatic detection and mammography screening sensitivity, under particular
(modelling) assumptions. For cohort data it will usually in addition, be possible to
estimate incidence rates [88] and evaluate risk factor associations.
2.3.2 Multi-state Markov models
Multi-state Markov models are the most common basis for modelling the natural history
of breast cancer and have been applied extensively in the literature, often based on data
from randomised screening trials [36, 88–90], but also on observational data [85, 91,
92]. The model assumes that a breast cancer passes through different discrete states in
its disease progression. Although the progression is discrete, time may be modelled as
continuous. The basic multi-state Markov model is based on the Markov property, i.e.
it is a memoryless stochastic process, which infers that the time spent in each state is
exponential. It means that the probability for the disease to be in a specific state at a
future time point is independent of the track record before the time point t, if the state at
time t is known [93]. In further assuming that the process is time homogeneous (does not
change with calendar time) it is possible to define a matrix P of transition probabilities
p jk(t) between states, such that p jk(t) = P(disease in state j has transitioned to state k, t
time units later). The matrix Q is the corresponding matrix of (immediate) transition rates
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Figure 2.12: A basic state space model for the natural history of breast cancer in
presence of screening.
q jk(t) between the states. If the state space is finite and P′ is the matrix of derivatives of
the transition probabilities, then P′ = PQ holds. If another distributional assumption than
exponential is made for the time spent in each state, the model is called a Semi-Markov
model [90].
The most basic Markov model for breast cancer data is in absence of screening and
only has two states: No detectable cancer and Clinical cancer, thus it includes only one
state transition. It can be used to estimate incidence of clinical disease. However, in
practice, standard regression techniques (generalised liner models, GLM’s) are used for
such evaluations. A three-state Markov model that has been applied more often in the
research literature is one for data in the presence of screening, which includes one extra
state between the two previously mentioned, called Preclinical cancer. This is the state
when the tumour is detectable at screening but not yet by symptoms and the time spent
in this state is called the sojourn time, as previously described (Section 2.2.3). In this
model two transition rates can be estimated, which we may call λ1 and λ2, see Figure
2.12 [88]. Mammography sensitivity in this model is the probability that a cancer in the
preclinical state is detected at screening [36]. Theoretically, the number of states to be
included in a multi-state Markov model is limitless, but in practice restricted according
to the size and type of data source that is going to be used. For instance, tumour size
may be incorporated such that there exists two preclinical states and two clinical states
with small and large tumours (similar to the model described by Uhry et al. [91] but
for lymph nodal involvement). Then transitions may occur from No detectable cancer
to Small preclinical cancer, from Small preclinical cancer to Large preclinical cancer or
Small clinical cancer, and from Large preclinical cancer to Large clinical cancer. In such
model screening sensitivity may be assumed to either differ between the two preclinical
states [89], or be the same throughout both states [91].
To estimate the transition rates and screening sensitivity, maximum likelihood
estimation (applying varying forms of likelihood functions [92, 94]) and Bayesian
methods [89] have, for example, been used. To the best of my knowledge, all of these
models require information on women at risk of developing breast cancer (i.e. has not
been developed for case-only data). Multi-state Markov models can also be used to
evaluate lead time and overdiagnosis [85, 95, 96], but tumour growth rates cannot be
directly evaluated, although they are strongly correlated to transition rates between
preclinical to clinical states. A commonly used lead time correction procedure for
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survival measures, described by Duffy et al. [96], is based on the three-state Markov
model. The approach is based on the assumption that lead times for screen-detected
cases follow the same exponential distribution as the sojourn times in the entire breast
cancer population. The correction procedure takes away the same amount of survival
time for all (screen-detected) women (it is unconditional on tumour characteristics,
screening history, etc.). It however ensures that no individual lead times exceed times to
breast cancer death from times of diagnosis.
2.3.3 Continuous tumour growth models
Both multi-state Markov models and continuous tumour growth models view time as
continuous. However, as opposed to multi-state models, which consider cancer
progression in terms of discrete events (from state to state), continuous tumour growth
models assume that tumours continuously (cell by cell) increase in size. Regional and
distant spread may still be described as discrete events. The models require an
assumption of how tumours grow over time. In this Section we present continuous
tumour growth models that make use of analytical methods for estimating unknown
model parameters.
Tumour growth laws
Different laws of tumour growth have been proposed for use in continuous tumour growth
models, based on varying kinds of evidence. The most basic tumour growth law is the
one assuming that tumours increase in volume exponentially [97], such that
dV
dt
= reV (t), (2.1)
where V is the tumour volume, t is time and re is the growth rate. From this model it
follows that the tumour volume doubling time is constant over time (= log(2)re ). The model
implies that the nutrition of the tumour does not cease with time. Among researchers
there is a general agreement that the exponential model is a valid assumption for early
tumour growth [97].
To allow for a decelerating tumour volume doubling time other growth laws have been
suggested. The power law model has the form
dV
dt
= rpV (t)α , (2.2)
where growth is decelerating for α < 1 and rp represents the growth rate. The generalised
logistic growth law has the form
dV
dt
= rlV (t)
(
1− (V (t)/K)β
)
, (2.3)
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where rl is the growth rate and K and β are constants.
Talkington and Durrett [97] used a small sample of screen-detected breast cancer cases
(previously described in Heuser et al. [98]) that could be seen on two mammograms
at different time points; at the diagnostic screening and at an earlier negative screening
(where the tumour was detected in retrospect). They found that the exponential growth
had a superior fit over power law, generalised logistic and Gompertz growth laws for
breast cancer tumours.
In previous work, Spratt et al. [99] used a similar, but larger data set of breast cancers
with more observations per woman over time. They concluded that tumour growth was
best described with a variant of the logistic growth function, together with lognormally
distributed tumour growth rates.
In more recent work on breast cancer tumours in mice, Hartung et al. [100] found
that breast cancer tumour growth was best described by Bertalanffy, West and Gompertz
models, which all involve an initial exponential growth phase.
Continuous tumour growth models in absence of screening
To model tumour size distributions for case-only data in absence of screening Atkinson
et al. [101] and Brown et al. [102] proposed to use a combined model of tumour growth
and symptomatic tumour detectability. For time to symptomatic detection they proposed
the use of a hazard function, dependent on tumour volume raised to some power α . Klein
and Bartoszyn´ski [103] found a good fit of the model for α = 1 (shown in Section 5.1).
For the tumour growth part Atkinson et al. [101] and Brown et al. [102] proposed the use
of an exponential tumour growth, with gamma distributed inverse tumour growth rates
to account for individual-to-individual variation (shown in Section 5.1). In work on lung
cancer, Bartoszyn´ski et al. [104] found that the model fit was superior when assuming
inverse tumour growth rates followed a gamma distribution instead of being deterministic.
Also, Brown et al. [102] found that the model fit to breast cancer tumour sizes was as good
for their proposed model as when assuming Gompertzian or logistic growth laws, which
are mathematically more complex.
The proposed submodels by Atkinson et al. [101] and Brown et al. [102], make it
possible to derive the tumour volume distribution in absence of screening, fVdet (v), as
shown by Plevritis et al. [87]. In their work, they also extended the modelling of tumour
sizes to include regional and distant stages by using similar hazard functions (as for
symptomatic detection) dependent on tumour volume. Parameter estimation was made
by maximising a product of three likelihood functions for tumour size, conditional on
tumour stage (local, regional or distant) at diagnosis. (In terms of analytical approaches
for estimation of parameters, maximum likelihood estimation has been the main
procedure used for continuous tumour growth models.) Using the same hazard function
for time to symptomatic detection, Chia et al. [105] assumed a more complex tumour
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growth model, described by a geometric Brownian motion. However, not all parameters
of interest in tumour growth and symptomatic detectability functions can be estimated
based on data in absence of screening [87].
Continuous tumour growth models in presence of screening
Continuous tumour growth models have been used sparsely for data in the presence of
screening. Weedon-Fekjær et al. [106] proposed the use of a model for tumour growth
and mammography screening sensitivity. For tumour growth they assumed the logistic
growth model presented by Spratt et al. [99] having the form
V (t) =
Vmax[
1+
((
Vmax
Vcell
)0.25
−1
)
e−0.25κt
]4 , (2.4)
where t is the time, κ is the growth rate assumed to follow a lognormal distribution, Vcell is
the volume of one cell, Vmax is the assumed maximum volume (corresponding to a tumour
diameter of 128 mm). For mammography screening sensitivity they proposed the use of
a logistic form, as a function of the tumour diameter at the time of screening, see Section
5.1.
Based on a well-defined cohort of women attending the Norwegian Breast Cancer
Screening Programme the authors presented a likelihood function in two parts to be used
for parameter estimation. The likelihood function modelled tumour sizes in screening
cases detected at the prevalent screen (without previous screen attendance) and incidence
of interval cases. In additional work [92] a likelihood function for tumour size in
screening cases detected at screens subsequent to the entry screen (given time since last
negative screening) was described. Instead of assuming a model for time to symptomatic
detection, as was done by Atkinson et al. [101] and Brown et al. [102], an additional
data set of tumour sizes in absence of screening (before the screening programme was
implemented) was used. To derive the probability of tumour sizes for screen-detected
cases, they applied back calculation from this external data source of symptomatic
tumour sizes.
Hanin and Yakovlev [107] had earlier described an (unrelated) approach (which was
mathematically technical but not in detail applied to real data) for constructing joint
likelihood functions for age and tumour size at detection for data in presence of
screening, which is applicable to data from randomised screening trials. They used the
previously mentioned tumour growth and symptomatic detection models of Atkinson et
al. [101] and Brown et al. [102], together with a discrete conditional hazard rate for time
at screen-detection, assumed to be proportional to tumour size (previously described by
Hanin [108]).
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2.3.4 Simulation-based approaches
As an alternative to using analytic methods to directly estimate parameter values in
natural history models, simulation-based procedures with model calibration against real
data can be used [109]. Chia et al. [105] suggested that Monte Carlo simulations provide
a useful tool in situations where a likelihood function is mathematically difficult to
derive. In a Monte Carlo simulation, or microsimulation, for breast cancer in presence of
a screening programme, the life-histories of many individuals can be simulated,
including events such as birth, screening exams, tumour onset and progression, clinical
diagnosis and death due to breast cancer or other causes [110]. These can be simulated
under pre-specified model assumptions, which can, for example, be of either nature –
multi-state model or continuous tumour growth model. As an example, Tan et al. [110]
used Monte Carlo simulations to estimate parameters for a lognormally distributed
tumour growth rate (assuming an exponential tumour growth), a Weibull distributed
threshold tumour size for screen-detection, and a lognormally distributed tumour size at
clinical diagnosis (for detection caused by the size of the primary tumour, distant
metastasis was however also a possible cause for symptomatic detection). The authors
calibrated their model against breast cancer specific survival stratified on tumour size
and detection mode based on data from the Swedish two county study, by repeatedly
evaluating simulated histories using the score function method in combination with a
quasi-Newton optimization procedure. However, different approaches to calibration are
possible. Unfortunately, researchers do not always describe explicitly how calibration
was carried out in such publications [109].
The CISNET consortium
Some of the studies mentioned in Section 2.3 have been carried out within the CISNET
Breast Cancer Working Group consortium, which was formed in 2000 to use statistical
and simulation modelling for evaluating the impact of different breast cancer control
strategies on incidence and mortality [64]. In the consortium for breast cancer, six
research groups (originally seven) developing six independent models are included.
Collectively these groups have produced many publications. The six models are called
Model D: The Dana Farber Model, Model E: The Erasmus MC MISCAN Model,
Model G: The Georgetown-Einstein Model, Model M: The MD Anderson Model,
Model S: The Stanford Model, Model W: The Wisconsin-Harvard Model. Some of the
models are based on multi-state (Markov) models for the natural history component and
some on continuous tumour growth models. Some estimate parameters using analytical
approaches, but mainly simulation-based approaches have been used. A recent highlight
presented by the consortium is the comparative study by Plevritis et al. [65], described in
Section 2.2, which concludes that the mortality reduction from screening is largest in the
group of women having ER- and HER2-receptor negative disease. The probability for
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this group to be detected at screening is however in general lower, see also Munoz et al.
[111].
Model E is presented in, for example, the already mentioned study by Tan et al. [110],
where the natural history parameters estimated by using a simulation-based approach
(already described in Section 2.3.4) were used as model inputs in the MISCAN-Fadia
model. This was done (also that by using a simulation-based approach) to evaluate the
reasons behind the mortality reductions seen in the U.S. population. The natural history
component in the MISCAN-Fadia model comprises one of four parts of the complete
simulation set up, the others describing the population, mammography screening and
adjuvant treatment.
Model D is the only model in CISNET for breast cancer that takes on an analytical
approach for estimating parameter values. In a recent development by Lee et al. [85]
from 2018, the natural history component (pre-death) consists of a six-state model, having
the same states as in a basic three-state Markov model, but also including preclinical
undetectable DCIS, preclinical screen-detectable DCIS and clinical DCIS with symptoms.
The sojourn time for invasive tumours is assumed to be exponential, but not for DCIS
tumours (abbreviation for ductal carcinoma in situ – these tumours are less aggressive
than the invasive ones). The authors also present analytical expressions for lead time
distributions, to be used for evaluating overdiagnosis – see results presented in Section
2.2.4. The natural history model component does not take tumour size/cancer stage into
account. Neither do the lead time and overdiagnosis expressions.
Model S is based on a Monte Carlo simulation procedure, producing life-histories of
women, which can be calibrated to U.S. mortality data [112]. For the natural history part
of the model, assumptions are similar to the ones used in Plevritis et al. [87], but include
a dependency of age and menopausal hormonal treatment on growth rates.
Screen-detection occurs if a tumour is larger than a specific threshold size at the time of
screening. Estimation of natural history parameters, including a hazard rate for time to
symptomatic detection, and one of the two unknown parameters of the inverse tumour
growth rate gamma distribution (under the assumption of one parameter being constant),
are made analytically based on data in absence of screening [113]. The other growth rate
parameter is fitted via a simulation-based approach, calibrated to U.S. incidence data, as
is the threshold for tumour size at screen-detection [113]. A new estimation procedure is
however being developed [112].
To briefly summarise the modelling of the natural history components in the
remaining models: Model G applies a multi-state model, Model W assumes tumours
grow exponentially and assumes a model described by Shwartz [114] and Model M
applies no natural history component [115, 116]. Overall, in the models, use of
mammographic breast density is limited. Half of the models (all of the ones assuming a
continuous tumour growth) are based on an exponential tumour growth law.
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3 Aims of this thesis
The overall aim of this thesis is to form the basis and show the potential, of a statistical
model for the natural history of breast cancer in presence of screening. It is hoped that the
model can be of value for future research in designing individual screening programmes.
The specific aims of the four studies are:
 To develop a novel statistical model that jointly estimates breast cancer tumour
growth rate, time to symptomatic detection and mammography screening
sensitivity as a function of percentage mammographic density.
 To enable and exemplify the use of covariates in all parts of the proposed
continuous tumour growth model and to explain the association between body
size and tumour size in terms of breast cancer tumour growth and time to
symptomatic detection.
 To show the strength of the continuous tumour growth model in terms of its ability
to identify novel image markers important for mammography screening sensitivity.
To quantify the role of scatteredness of dense tissues in mammography screening
sensitivity, in relation to percentage mammmographic density.
 To derive lead time distributions on an individual basis and use these to develop a
novel lead time bias correction to be used in survival comparisons between
screening and symptomatic cases. To extend the traditional view of length bias.
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4 Data material
In this thesis, both observational and simulated data on postmenopausal breast cancer
cases have been used. In this Section the use of observational, case-only, data is described,
while data simulations are briefly explained in Section 5.6.
Swedish registries and linkage between them
In Sweden there are six Regional Cancer Centres (RCC’s) which originate from 1958
and nowadays are responsible for the Swedish Cancer Registry [117]. It is compulsory
for physicians and e.g. pathologists, to report all diagnoses of malignant cancers to the
registry. The registry includes information on date and basis of diagnosis and cancer
invasiveness. It also has a high completeness.
All persons born in Sweden or living in Sweden for at least a year are registered in
the Swedish Population Register, held by the Swedish Tax Agency [118]. The register
includes information on, for instance, addresses and personal identity numbers (a 10-digit
identifier that is unique to each Swedish resident). For medical researchers registries such
as these may be linked upon request, through the personal identity number, if ethical
permission has been given by an Ethical Review Board.
CAHRES
CAHRES (Cancer Hormone Replacement Epidemiology in Sweden) is a case-control
study, which includes cases diagnosed with incident primary invasive breast cancer
between October 1993 and March 1995 and age-matched controls. Its original aim was
to study the effects of HRT on breast cancer risk [119]. The study included women
between 50-74 years old and the study base was determined using the Swedish Cancer
Registry, through which 3979 women were found to be eligible cases. Out of these 3345
cases (84%) participated in the study and from most of these women questionnaire data,
as well as information from medical records, were available. In extensions of the study,
information on screening history (up until five years prior to diagnosis) and
mammograms were collected from radiology departments and mammography screening
units in Sweden [40]. In this thesis, only cases have been included.
Study populations
While Study IV makes use of simulated data, Studies I-III are (partly) based on
observational data, all originating from the same source population, CAHRES. For all
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study populations women without written consent, with a previous or other cancer
diagnosis (except from non-melanoma skin cancer), with a noninvasive breast cancer or
with a diagnosis made outside the study period, were excluded. As breast cancers tend to
differ depending on menopausal status, see Section 2.1.3, only the group of
postmenopausal women has been studied. Analysing the premenopausal cases separately
would lead to low statistical power, due to the original age inclusions of CAHRES. For
women with unknown age at menopause, the 90th percentile of 55 years at menopause
was used as a cut-off value for inclusion. A flowchart for the study populations is
presented in Figure 4.1. Study I consisted of 1370 cases, Study II of 1352 cases and
Study III of 1845 cases. This thesis work has been carried out continuously over a long
time period and quality checks of the data have also been made continuously, which has
resulted in some differences between the study populations. The main difference being
the inclusion of more women in Study III due to more mammograms being available.
The main focus of this thesis is on methods development. The number of variables
used has been few but these have been chosen with care.
Tumour size
Throughout this thesis breast cancer tumour size provides the main information used for
statistical modelling. (The importance of tumour size in relation to e.g. survival has been
exemplified in Section 2.1.1.) In the data, tumour size represents the maximum distance
of the tumour in mm, measured from pathologists’ examinations of tumours removed at
surgery. If a woman had more than one tumour in a breast, the largest one was recorded.
The variable is continuous, although it is clear from inspection that pathologists tend to
approximate tumour sizes to the nearest 5 or 10 mms. For larger tumours,
approximations appear to be coarser. Because the use of neoadjuvant chemotherapy,
before surgical removal, can downsize tumours [120], women receiving this treatment
were excluded in Studies II and III.
Detection mode
How a breast cancer case was detected (by symptoms or at screening) is recorded as a
binary variable. Reasons for mammography/diagnosis were retrieved from the records
where mammography was performed, as well as from the medical records. Women with
conflicting information were excluded in Study III. A further refinement in Study III was
that women were excluded if reason for mammography was recorded as being control or
no reason. In Studies I and II, these women were coded as screen-detected cases.
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Eligible cases for
CAHRES (n=3979)
Excluded (n=634):
– Did not wish to participate
(n=3345)
Excluded (n=320):
– No written consent
– Previous/other cancer diagnosis
– Noninvasive cancer
– Diagnosed outside study period
(n=3025)
Excluded (n=345):
– Premenopausal (n=177)
– < 55 years and unknown age at
menopause (n=168)
(n=2680)
Studies I and II Study III
Excluded (n=700):
– Unknown cause for diagnostic
mammogram (n=67)
– Unknown tumour size (n=36)
– Missing information on screening history
(n=597)
Refined exclusions (n=558):
– Unknown cause for diagnostic
mammogram (n=200)
– Unknown tumour size (n=60)
– Missing information on screening history
(n=265)
– Received neoadjuvant treatment (n=33)
– Missing mammogram (n=277)
Study III population (n=1845)
(n=1980)
Study I Study II
Excluded (n=610):
– Missing Cumulus-measurements
Excluded (n=628):
– Unknown BMI (n=10)
– Received neoadjuvant treatment (n=27)
– Missing Cumulus-measurements
(n=591)
Study I population (n=1370) Study II population (n=1352)
Figure 4.1: Flow chart of study populations in Studies I, II and III.
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Screening history
Information on screening history was searched for from five years until three months
before diagnosis of breast cancer. The three months cut-off was used to avoid wrongly
including any mammography included for the diagnosis work-up, as part of the screening
history of negative screenings. In the analysis, a maximum number of three negative
screenings were used. In the questionnaire to the cases, women were asked about whether
they had been to screening and how many times. We excluded women who answered that
they had been to screening at least once (Studies I-II) or more than once (Study III) the last
five years, but had no data on negative screen occasions. The refined exclusion for Study
III was made, since it is not clear from the questionnaire that only negative screenings
should be considered.
BMI
BMI was calculated from questionnaire data of weight and length of the women at study
entrance (post-diagnostic values). The women were also asked about their weight one
year before study entrance and the differences in values between the two variables were
small.
Percentage mammographic density
Studies I and II
In Studies I and II, we aimed to use the semi-automated "golden-standard"
Cumulus-measurements of percentage mammographic density already available from an
extended study of CAHRES [40], produced by a trained observer. Thus, one
mammogram per woman was selected for inclusion in the studies – the mammogram
closest to (before) diagnosis in the contralateral breast, to avoid the appearance of
tumours. Only mammograms of mediolateral oblique view (MLO) were considered.
However, approximately 600 cases had to be excluded due to missing mammograms or
Cumulus-measurements.
Study III
To further increase statistical power we decided to, instead of using the
Cumulus-measurements for percentage mammographic density, use the corresponding
measurements from an automatised procedure [75]. Such measurements are not
time-consuming to provide and thus they could be produced for, close to, all collected
mammograms. However, to some recorded screen occasions mammograms had not been
retrieved. All contralateral (MLO-view) mammograms available between the years
1988-1997 were included in the study. For each woman the average PD of all her
included mammograms were used in the analyses, to reduce measurement errors.
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Scatteredness of dense tissues
In Study III, as a proxy for the scatteredness of dense tissues, the technical measure of
Skewness of the intensity gradient, described by Cheddad et al. [77], was used. The
same set of mammograms as for PD were included for analyses and for each woman the
average SI of all her included mammograms was used.
Breast size
We did not have a perfect measure of breast size available for Study II, rather a proxy for it,
total breast area, TBA, was used. TBA measures the amount of pixels on a mammogram,
which together constitutes the dense and non-dense areas. TBA was available for the
same mammograms as PD and was measured by the same observer.
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5 A novel continuous tumour growth model
In this thesis, a novel continuous tumour growth model for data in presence of screening
is presented. The model consists of three submodels: tumour growth, time to
symptomatic detection and mammography screening sensitivity. It is the first continuous
tumour growth model that analytically and jointly estimates the three processes, while
allowing for inclusion of covariates in all parts of the model. It does not model the onset
of tumours and can thus be used for case-only data (i.e. does not need data on the
complete set of at-risk individuals). The model has a closer link to tumour biology, than
the multi-state Markov models presented in Section 2.3.2, which use discrete tumour
progression from state to state. All processes in the continuous tumour growth model
include tumour size as a continuous variable, which plays the major role in the modelling
framework. The natural history submodels for tumour growth and symptomatic detection
are adopted from previous works for data in absence of screening [87, 101, 102, 104].
The submodel for screening sensitivity comes from Weedon-Fekjær et al. [92, 106]
whose work has also inspired the maximum likelihood estimation (MLE) procedure.
5.1 Modelling of three latent processes
Following is a description of the main modelling framework proposed in Study I, based
on tumour size at diagnosis, without inclusion of covariates. The main model consists of
five unknown parameters.
Submodel for tumour growth
The first submodel is for tumour growth, which is assumed to be exponential. To allow
for heterogeneity in growth rates the model includes a gamma-distributed random effect
for inverse tumour growth rate, R. Tumours are assumed to be spherical and t years after
tumour onset, the volume (in mm3) is specified as
V (t,r) =V0et/r, t ≥ 0,r > 0. (5.1)
V0 represents the tumour volume from when time starts to count (tumour onset) and may
for instance represent the volume of one cell, or a small tumour volume not yet
detectable by screening. r is a realisation from the random effects model with shape and
rate parameters τ1 and τ2, such that
fR(r) =
ττ12
Γ(τ1)
rτ1−1e−τ2r, r ≥ 0. (5.2)
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Submodel for time to symptomatic detection
The second submodel is a hazard function for time to symptomatic detection, assumed to
be dependent on the tumour volume through
P(Tdet ∈ [t, t+dt)|Tdet > t,R = r) = ηV (t,r)dt+o(dt), V (t,r)≥V0, (5.3)
where η is a constant and Tdet is the time for symptomatic detection, in absence of
screening.
Submodel for mammography screening sensitivity
The third submodel is for mammography screening sensitivity and enables modelling of
data in presence of screening. It assumes the logistic form
S(d) =
exp(β1+β2d)
1+ exp(β1+β2d)
, (5.4)
in which β1 and β2 are constants and d is the tumour diameter in mm.
5.2 Natural history model covariates
As mentioned, the three latent processes described in Section 5.1 are all linked to tumour
size. By using regular statistical techniques such as regression modelling, it is possible,
in breast cancer cases, to find covariates that are associated with tumour size. Shedding
light on the mechanisms behind the associations is however more difficult. Inclusion of
covariates into the latent processes described herein, has the potential to increase
knowledge regarding why some women are diagnosed with larger tumours than others.
This makes our natural history model useful in the development of individual screening
programmes. This Section presents the proposal (from Studies I and II) of how
covariates may be included in the different parts of the continuous tumour growth model.
Submodel for tumour growth
For the gamma distributed inverse tumour growth rate (5.2), it holds that E(R) = τ1τ2 and
Var(R) = τ1τ22
. In Study II we propose to do a mean reparametrisation, so that E(R) = τ1τ2 =
µ and Var(R) = τ1τ22
= σ2µ2, in which σ is the constant coefficient of variation. We model
log(µ) = α1+α2x1+ ...+αn−1xn, (5.5)
in which x1 to xn represents the covariates to be included. The parameters
α1,α2, ...,αn−1,σ will be estimated instead of τ1 and τ2. Using this parametrisation
enables modelling of covariate effects on the mean inverse tumour growth rate. In Study
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II, we include BMI as X1, for unravelling whether the association between body and
tumour sizes is due to tumour growth rate and/or symptomatic detectability.
Submodel for symptomatic detectability
For the hazard function (5.3) we propose in Study II, to allow for inclusion of covariates
by letting
log(η) = λ1+λ2z1+ ...+λn−1zn. (5.6)
Parameters to estimate are λ1,λ2, ...,λn−1. In Study II we include TBA (a determinant for
breast size) as z1.
Submodel for mammography screening sensitivity
As proposed in Study I, for the screening sensitivity function (5.4) covariates
q1,q2, ...,qn−2 may be included as
S(d,q1,q2, ...,qn−2) =
exp(β1+β2d+β3q1...+βnqn−2)
1+ exp(β1+β2d+β3q1...+βnqn−2)
. (5.7)
This is done in Study I (PD and interaction term with d), Study II (PD), Study III (PD and
SI) and Study IV (PD), for quantification, testing or confounding purposes.
5.3 Estimation procedures
In Studies I-III, estimation of the unknown parameters in the three latent processes are
based on maximum likelihood estimation, MLE. A likelihood function is the probability
of the observed data, as a function of the unknown parameters [121]. Let θ be a vector
consisting of the parameters to be estimated and let o1, ...,on be realisations from the
discrete random variables O1, ...,On following probability mass functions
P1(O1 = o1;θ ), ...,Pn(On = on;θ ) = p1(o1;θ ), ..., pn(on;θ ). Then the likelihood
function can be written as
L(θ ) =∏
j
p j(o j;θ ). (5.8)
Further let θˆML be the estimate of θ that maximises the likelihood function. As the
logarithm of a function is strictly monotone, an equivalent estimate can be found from
maximising the log-likelihood function (often numerically more convenient) [122]
l(θ ) = log(L(θ )) =∑
j
log(p j(o j;θ )). (5.9)
The profile likelihood function divides the set of unknown parameters into parameters
of interest θ i and nuisance parameters θ n. In this function, the parameter values for the
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nuisance parameters may be set to the values obtained from MLE of (5.8), so that these
parameters are seen as fixed constants.
5.3.1 Point estimation
In this thesis O1, ...,On represent random variables, for the n included cases, of tumour
size diameters (in mm) at diagnosis. The tumour size in each case j, follows an individual
probability distribution Pj, conditional on detection mode, screening history and possibly
other covariates. Further, tumour sizes are categorised into intervals I, indexed with i, and
are assumed to follow multinomial distributions, so that
p j(o j;θ )≈∏
i
Pj(O j ∈ Ii;θ )oi, j , (5.10)
where oi, j is 1 if the tumour in woman j is detected in size interval i, and 0 otherwise. We
let Pj(O j ∈ Ii;θ ) be written as pi, j, which in words read: the probability for the tumour in
woman j to be detected in size interval i, given the detection mode and screening history
of woman j. Screening history is measured as the difference in days between the time
of diagnosis and previous negative screenings. This implies that most of the probability
distributions Pj are unique, except, for instance for symptomatic cases without screening
history. The complete likelihood is written as
L(θ ) =∏
j
∏
i
pi, joi, j , (5.11)
and includes approximation and summation steps, thus no closed-form solution is
available. A similar likelihood function setup was described by Weedon-Fekjær et al.
[92, 106], with the main difference that, for interval/symptomatic cases, we propose
modelling of tumour size, instead of modelling the incidence of interval cases (which
requires data on all women at risk of getting breast cancer). For calculations of pi, j,
based on (5.1)-(5.4), see Section 5.4.1.
Optimisation procedure
Optimisation of (5.11) was carried out using the modified quasi-Newton optimisation
procedure presented by Byrd et al. [123] by the optim function in the statistical program R
[124], using the option L-BFGS-B. The method described by Newton for finding extreme
values of functions, requires analytical solutions of e.g. the Hessian matrix, whereas the
quasi-Newton methods, such as the BFGS-algorithm [125], use approximate values. The
modified method used in this thesis has been developed to require less computational
memory for optimisation of parameters.
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5.3.2 Variance estimation and p-values
Due to a complex likelihood function, computer-intensive, numerical methods are used
not only for point estimations, but also for evaluating the variability of the parameter
estimates.
Likelihood ratio test
Let us assume that we have two nested models. We call the model with more parameters
the alternative model and the model with fewer parameters the null model. Let L1 be
the optimised likelihood function value for the alternative model and L0 the optimised
likelihood function value for the null model. We define the likelihood ratio as
Λ=
L0
L1
. (5.12)
Following an important result by Wilks [126] we then use that −2log(Λ) (for large n)
approximately follows a χ2d -distribution, where d is the difference in dimensionalities of
the models, to calculate p-values. We use this test to study the importance of parameter
inclusion in Studies I-III.
Profile likelihood point wise confidence interval
In Studies I and II, the profile likelihood function was used to produce 95% point wise
confidence intervals. The procedure is based on using the same (approximate)
distributional assumption as for the likelihood ratio test above. When creating a point
wise confidence interval for a parameter estimate θˆML, the profile likelihood function
was evaluated (optimised) for several different values of θ , to find for which values the
MLE corresponded to a 95% confidence interval according to the quantiles of the
χ21 -distribution [127].
Non-parametric bootstrap percentile confidence interval
Non-parametric bootstrapping is a resampling procedure, which may be used to estimate
quantities such as the variance or confidence intervals of an estimator. Each bootstrap
sample consists of n values, sampled with replacement, from the original sample of the
same size n [128]. For each of the m drawn bootstrap samples the same estimation
procedure (in this thesis MLE) is used as for the original sample, which creates a set of
m bootstrap estimates for each parameter θ . When creating a 95% percentile confidence
interval for θ , the range of the 95% least extreme values of the bootstrap estimates are
presented, such that the same number of points are excluded from both sides of the
interval. This method has been applied in Studies I-III.
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Non-parametric bootstrap percentile test
In Study I non-parametric bootstrap percentile tests were carried out, using the same
sampling technique as above. The p-value related to a null hypothesis such as H0 : θ = 0
was approximated by twice the value for the fraction of bootstrap estimates being below
or above 0, according to the least common direction of the bootstrap estimates.
5.4 Calculations of conditional probabilities
The continuous tumour growth model framework presented in functions (5.1)-(5.4), along
with additional assumptions of a stable disease population, make it possible to derive
individual (conditional) distributions for different variables, both variables observable at
diagnosis and latent, unknown variables. In comparison to unconditional distributions
of variables that apply to all women in a population, conditional distributions may be
helpful for studying individual screening programmes. In this thesis, some conditional
probability distributions are presented. See Isheden and Humphreys [129] for further
derivations. Observable variables may be used for derivation of likelihood functions (in
this case for tumour size) and latent variables (such as lead time and tumour growth rate)
may be used for bias corrections.
Assuming a stable disease population means that the rate of breast cancer onset is
constant over time in the population and that the distributions for age at tumour onset and
time to symptomatic detection is constant across calendar time.
5.4.1 Tumour size
The likelihood function (5.11), which includes the conditional probabilities pi, j for
tumour size at diagnosis, resembles the likelihood function presented in Weedon-Fekjær
et al. [92, 106]. They derived pi, j for screen-detected cases, but instead of modelling
tumour size for symptomatic cases, they modelled the incidence of intervals cases.
Calculations for tumour sizes at screen-detection were based on calculating backwards
from a data set with tumour sizes in absence of screening (no model for symptomatic
detection was assumed). In Study I, pi, j (also used in Study II) is presented for both
screen-detected and symptomatically detected cases conditional on screening history.
The derivations are based on back calculation from the symptomatic tumour size
distribution in absence of screening (i.e. no external data set of tumour sizes in absence
of screening is needed). In Study III a recently developed, less computer intensive
derivation of pi, j [129] is used.
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Studies I and II
Based on functions (5.1)-(5.3), Plevritis et al. [87] derived the marginal distribution for the
volumes at symptomatic detection, fVdet (v), as well as the conditional distribution, given
inverse tumour growth rate, fVdet |R=r(v). The latter is especially useful for simulating the
natural history of breast cancer. In Study I, we present the reverse conditional distribution,
using the lower incomplete gamma function, as
FR|Vdet=v(r) =
γ(τ1+1,r(τ2+η(v−V0)))
Γ(τ1+1)
, v≥V0, (5.13)
which is applied in the back calculations from the symptomatic tumour size distribution
in absence of screening to the tumour sizes at positive or negative screen exams, used in
the derivations of pi, j (Section 5.3.1).
To briefly describe the conditional probabilities for tumour size (pi, j), let woman j
have a screening record of k screenings, then jk is the time point for her last (positive or
negative) screen exam, jk−1 is the time point for her second last screening, etc. and Bcjk is
the event that a tumour in woman j was not detected at any of the screening rounds 1 to
k. Further let Ci, j,t be the event that a tumour in woman j at time point t is in size interval
i (which corresponds to a tumour diameter of di, j). Also let D j,t, f imply that a tumour in
woman j was supposed to be symptomatically detected f time units after the time point t
in absence of screening, and Ag, j be the event that the cancer would have become clinical
for woman j in tumour size interval g, in absence of screening. (Using the index j in all
events allows us to consider different covariate values for each individual, to be included
in the three submodels – Section 5.2.)
Then for screen-detected cases it is shown in Study I that, approximately,
pi, j ∝ S(di, j)·∑
s
P(Bcjk−1 |Ci, j, jk∩Cs, j, jk−1)P(Cs, j, jk−1 |Ci, j, jk)·∑
f
∑
g
P(Ci, j, jk |D j, jk, f ∩Ag, j)P(Ag, j),
(5.14)
where the sum over s (tumour size at last negative screening) is removed for screen-
detected cases without previous screening exams. In the above formulae S(di, j) is the
mammography screening sensitivity function (5.4) at the diagnostic screen exam. The
sum over s includes the probabilities of masking at all previous screenings (conditional
on tumour sizes at the screenings) and the probability that the tumour was in size interval
s at the last screening before the diagnostic one. The double sum is an approximation
of P(Ci, j, jk), in which, the previously mentioned, back calculations from tumour size
intervals at symptomatic detection, g, to tumour size intervals at the positive screen exam,
i, are used, allowing for all lead times, f . For the double sum, distributions of Vdet as well
as R|Vdet (5.13) are used.
For symptomatically detected cases it is shown in Study I that
pi, j ∝ P(Ai, j) ·∑
s
P(Bcjk |Ai, j ∩D j, jk, f ∩Cs, j, jk)P(Cs, j, jk |D j, jk, f ∩Ai, j), (5.15)
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where the sum over s is similar to the one in the conditional probability (5.14).
Distributions of Vdet and R|Vdet as well as the mammography screening sensitivity
function (5.4) are used.
The derivation of P(Cs, j, jk−1 |Ci, j, jk) in the conditional probability (5.14) is
unfortunately not optimally presented in Study I, where it was calculated by using an
approximation of the distribution R|Vdet > v. An improved calculation of this probability
could instead be
P(Cs, j, jk−1 |Ci, j, jk) =∑
r
P(Cs, j, jk−1 |R ∈ r∩Ci, j, jk)P(R ∈ r|Ci, j, jk), (5.16)
where r represents an inverse tumour growth interval. For calculations of the latter
probability, the derived distribution for R|C = c shown in Isheden and Humphreys [129]
may be used, where C represents the volume of a tumour in a non-screened, stable
population at any point in time, i.e. not specifically at symptomatic detection such as for
Vdet .
Study III
In Study III a novel derivation of the conditional probability for screen-detected cases
[129] is used, to increase computational efficiency, which was acquired by finding an
analytical solution for the complex quantity P(Ci, j, jk). This made it possible to remove
the back calculation ∑ f ∑g P(Ci, j, jk |D j, jk, f ∩ Ag, j)P(Ag, j) in (5.14). Also the derived
probability P(Cs, j, jk−1 |Ci, j, jk) by Isheden and Humphreys [129] was used, similar to the
solution in (5.16).
5.4.2 Tumour growth rate and lead time
The conditional distribution for the latent variable inverse tumour growth rate, given
tumour size at symptomatic detection (for women without previous screenings) (5.13)
was derived in Study I. Isheden and Humphreys [129] derived the distribution for the
inverse tumour growth rate, conditional on tumour size at screen detection for cases
without screening history (R|C). In Study IV, based on their results, we show the
distribution for the inverse tumour growth rate, conditional on tumour size at screen
detection for cases with previous recorded screenings. A similar approach may be used
for deriving the distribution for the inverse tumour growth rate, conditional on screening
history and tumour size at symptomatic detection.
In Study IV we also present (individual) lead time (L) distributions for screen-detected
cases, conditional on screening history and PD. Additional covariates, if jointly estimated
in the continuous tumour growth model, are straightforward to include.
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5.5 Lead time bias correction
Based on the conditional lead time distributions presented in Study IV we develop a
procedure for correcting of lead time bias in survival comparisons. The procedure
includes sampling a lead time, l∗, for each woman based on her individual distribution.
If s represents the observed survival time measured from screen detection, then s− l∗
serves as an estimate of the survival time measured from when the symptomatic
detection would have occurred in absence of screening. Conditional on observed survival
times, the conditional lead time distributions also make it possible to estimate the
probability for a woman to be overdiagnosed, which occurs when the mathematical
relation s−L < 0 holds. The correction is adapted to handle women dying from breast
cancer, but also censored women/women dying from other causes.
5.6 Simulation studies
Simulation studies are present in Studies I-IV to evaluate derived methodology. They
have also been used to compare our methods to other described in the literature. In the
simulations, life histories of breast cancer cases are produced, based on our described
continuous tumour growth model, with a few exceptions. Focus has been on the time
from tumour onset to detection by screening or symptoms, but, additionally in Study IV,
breast cancer specific survival (in presence and absence of a screening programme) was
simulated. Screen attendance is assumed complete throughout the studies and screening
occurs every other year. The emphasis of the simulations has not been to make them
fully realistic for evaluating screening programmes, but rather they are used as a tool to
answer/show implications of specific methodological questions.
Dependence of tumour growth rate and symptomatic tumour size
In the studies by Weedon-Fekjær et al. [92, 106] a model for symptomatic detection was
not assumed. This implies in our setting that distributions for Vdet and R|Vdet cannot be
derived. Instead, an external data set of tumour sizes in absence of screening may be
used. Also, in the derivations of the likelihood function (i.e. in the probability
P(Ci, j, jk |D j, jk, f ∩Ag, j)), use of the distribution of R instead of R|Vdet , implies that the
variables R and Vdet are assumed to be uncorrelated. In Study I, under our continuous
tumour growth model, we evaluate the implications of not assuming a submodel for
symptomatic detection. For comparing our estimation procedure to a method without a
symptomatic detection submodel, we compared MLE’s using a distribution for R|Vdet
instead of R and also using the derived distribution for Vdet (which vary throughout the
optimisation procedure as different sets of parameter values are evaluated) instead of a
fix tumour size distribution based on simulated data.
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Detection of image markers related to screening sensitivity
Strand et al. [76] used logistic regression with interval vs. screen-detected cancer as the
depedendent variable (i.e. only screen attenders are included) to find image markers of
MD from mammograms related to being an interval case. In a logistic regression, the log
odds for being an interval case is modelled as
log
(
pi
1−pi
)
= α0+α1X1+ ...+αpXp, (5.17)
where the variables X1, ...,Xp are the independent ones, pi = P(interval case) and 1−pi =
P(screening case).
In Study III we simulate data under our continuous tumour growth model, including
an image marker affecting mammography screening sensitivity. We also simulate data
under the tumour growth law (2.4) to take into account model misspecifications. We
compare the statistical powers, to detect image markers related to mammography
screening sensitivity, of the logistic regression model (with p = 1) and the approach of
including a covariate in the mammography screening sensitivity submodel (5.4) of our
continuous tumour growth model. The same set of women are included in both
procedures. For generalisation purposes, several different inverse tumour growth rate
distributions were used in the exponential tumour growth function (5.1).
Lead time bias correction on stratified data
Duffy et al. [96] proposed the use of a lead time bias correction for survival
comparisons, based on the basic three-state Markov model (using exponentially
distributed sojourn times), see Section 2.3.2. In the model, the lead time follows the
same distribution as the sojourn time. Slightly simplified, the correction procedure is
based on subtracting the mean, unconditional, sojourn time (which equals the mean lead
time) from the screen-detected cases’ survival times. For this reason we call this
correction the average correction.
In Study IV we perform a simulation study based on our continuous tumour growth
model, together with an exponential time to breast cancer death measured from the time
the tumours would have been symptomatically detected in absence of screening. This is
done to ensure that no women die before their lead times have passed. We stratify the
screen-detected cases into equally sized groups based on the median tumour size at
diagnosis in presence of screening. Then we perform the average correction by first
estimating the mean sojourn time in the complete simulated data cohort in presence of
screening [92], followed by subtracting it from each woman’s survival time. On the
stratified data we compare this procedure to the individual correction proposed in Study
IV, and to the true values from the simulation. (A comparison on unstratified data was
also performed).
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Length-biased sampling and the effect of length bias on survival comparisons
In Study IV, to evaluate the length biased-sampling and to increase our understanding of
the bias on survival comparisons, we perform a simulation study. To enable a length bias
and an effect of the stage shift, we make breast cancer specific survival dependent on the
tumour size at diagnosis and the tumour growth rate. Survival times are recorded for all
women under two different counterfactual scenarios; in the presence, Spres, and absence,
Sabs, of a screening programme. As sojourn times are not defined in continuous tumour
growth models, we instead propose the use of tumour presence times which is the time
from when the tumour was of a specific small tumour size (we use a diameter of 2 mm)
until the time it would have become symptomatically detected, in absence of screening.
Based on our continuous tumour growth model and parameter estimates presented in
Isheden and Humphreys [129], we compare tumour presence times between
screen-detected and interval cases to evaluate the length-biased sampling. We also
compare the factors affecting it; in our model inverse tumour growth rates and
symptomatic tumour sizes.
To study the effect of length bias on survival comparisons, together with the effects of
stage shift and lead time, we compare different measures of survival times. Specifically
we compare observed survival for screen-detected cases, lead time corrected survival for
screen-detected cases, survival for screen-detected cases in absence of screening and
observed survival for interval cases.
5.7 Computational aspects and practicalities
Programming for all studies in this thesis has been done by using the statistical program
R [124]. All of the studies use methods that are computationally intensive, both for
producing simulated data sets, but most of all in the evaluations of the likelihood
function (5.11). This implies that applying bootstrap methods for producing variance
estimations, takes a long time. Analyses in Studies I-III have been especially
time-consuming. Inclusion of covariates in the inverse tumour growth rate distribution
and time to symptomatic detection function involve additional computations compared
to including covariates in the mammography screening sensitivity function (Study II). A
large number of likelihood evaluations were required in the simulation study (Study III).
However, computational speed was much higher (computational time being reduced by
88% [129]) in Study III, than it was in Studies I and II, due to the fact that, in Study III,
back calculation in the likelihood evaluation procedure could be removed by the inclusion
of a closed-form solution.
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6 Main results
In this Section the main results from Studies I-IV are presented; firstly the methodological
evaluations, followed by quantifications and tests based on observational data and lastly
simulation-based results.
6.1 Methodological evaluations
6.1.1 Joint estimation of three latent processes
In Study I we found that when simulating data in presence of screening, under our
proposed continuous tumour growth model, we could learn the correct values of the
parameters within the submodels of tumour growth rate, screening sensitivity and time to
symptomatic detection. In Study II we evaluate the effect of inclusion of covariates in
different parts of the model, especially the inverse tumour growth rate and the time to
symptomatic detection submodels. Data was simulated under our continuous tumour
growth model, including a covariate in either, or both, of the two submodels. Effects
were identifiable as long as the covariate was included in both submodels.
As described in Section 5.6, by not assuming a submodel for time to symptomatic
detection in the continuous tumour growth model framework described by
Weedon-Fekjær et al. [92, 106], the likelihood function evaluations have to be based on
the assumption that tumour growth rate and symptomatic tumour size are independent
variables. Under our proposed continuous tumour growth model, we could show that,
basing the likelihood functions on such an assumption leads to biased estimates of
tumour growth rate and screening sensitivity. Our model relaxes this assumption.
6.1.2 Lead time and bias correction
In Study IV we show the derived individual lead time distributions, conditional on tumour
size at screen-detection, screening history and PD. Other covariates are straightforward
to include/condition on. To illustrate this, individual lead time distributions based on
TBA and tumour sizes for screen-detected cases with no screening history are shown
in Figure 6.1, based on parameter estimates from Study II (allowing for TBA to affect
time to symptomatic detection and BMI to affect inverse tumour growth rate). TBA is
standardised based on the observational data used in Study II.
Further, in Study IV, we make use of simulated data under our continuous tumour
growth model, together with exponentially distributed times to breast cancer death
(measured from the time of when symptomatic detection would have occurred in
absence of screening). We show that the proposed lead time correction (Section 5.4.2)
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Figure 6.1: Individual lead time distributions for screen-detected cases based on
tumour sizes (TS) of 10 and 15 mms and standardised total breast areas (TBA) of -2
and 2, based on the inverse tumour growth rate distribution according to the mean
BMI seen in Study II.
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gives unbiased survival times measured from symptomatic diagnosis, for all
screen-detected cases grouped together, as well as stratified on tumour size at diagnosis
(being below or above the median value).
For the average correction (see Section 5.6) using unconditional lead time distributions,
lead time corrected survival times for screen-detected cases, stratified on being below or
above the median tumour size at diagnosis, were biased. In general, use of unconditional
lead time distributions results in an undercorrection for small tumours (taking away too
short lead times) and an overcorrection for large tumours (taking away too long lead
times). This result can also be extended to other variables than tumour size, that both
affect the lengths of lead time and survival time.
6.2 Quantifications and tests
For the overall continuous tumour growth model, the most updated parameter estimates
for tumour growth rate, mammography screening sensitivity and time to symptomatic
detection, are presented in Study III. In Figure 6.2 these are summarised (using the
median value of SI in the population for plotting screening sensitivity). The
quantification of tumour growth (to the left) is presented as the time in years it takes a
tumour to increase in diameter, relative to the time it was 15 mm in diameter. It can be
seen that the individual-to-individual variation in growth rates is estimated to be large.
On the right-hand side of Figure 6.2 probabilities of detecting a tumour are shown,
comparing screening sensitivity to symptomatic sensitivity. Screening sensitivity refers
to the probability of tumour detection at a screen exam (not a process in continuous
time). The symptomatic sensitivity is presented as a cumulative probability that the
tumour would have been detected by symptoms at a specific tumour size, in absence of
screening (conditional on the estimated median tumour growth rate).
6.2.1 Mammography screening sensitivity in light of mammographic
density
Mammography screening sensitivity has been quantified in Studies I-III. In Study I we
presented novel estimates of the relationship between PD and tumour size (considered
jointly) with mammography screening sensitivity. A high PD was found to lower
screening sensitivity (p-value=4 · 10−3). When both PD and tumour size had been
included in the model, an interaction effect between the two was not significant. In Study
II, controlling for body size in the submodels for tumour growth and time to
symptomatic detection, had the effect of narrowing the confidence intervals for all
parameters included in the sensitivity function. PD was significant (p-value=6.3 · 10−4).
In Study III, without controlling for body size, the corresponding p-value for PD was
5.7 · 10−3. The role of PD and tumour size in mammography screening sensitivity is
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Figure 6.2: Quantification of tumour growth heterogeneity (left) and screening and
symptomatic sensitivites (right).
presented in Figure 6.3 (to the right). 95% confidence intervals, received from 200
nonparametric bootstrap samples are also presented. The PD values of 0 and 100% have
been plotted for comparison purposes, although in the data set, no woman has a value
higher than around 85%.
In Study III a similar quantification, but for the role of SI (measuring scatteredness of
mammographically dense tissues) in mammography screening sensitivity was presented
(see Figure 6.3 to the left). Since SI was normalised, it ranged between 0-1, but higher
values were more common than lower (see Study III). Comparing the quantifications for
PD and SI in mammography screening sensitivity, it can be seen that the use of SI better
distinguishes between which women that have a high compared to low sensitivity at
different tumour sizes. P-values from likelihood ratio tests, explaining the additional
effect of an image marker, when the other one was already included in the sensitivity
model, were 0.76 for PD and 5.6 ·10−4 for SI.
6.2.2 The association between body size and tumour size
Studies based on regular statistical regression models have shown positive associations
between body size and tumour size at diagnosis [32, 34, 48]. However, with these
standard techniques it is not possible to draw any conclusion regarding the reason(s)
behind the associations. In Study II we include BMI as a covariate in the model for
inverse tumour growth rate and TBA as a covariate in the model for time to symptomatic
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Figure 6.3: Quantification of mammography screening sensitivity as a function of
tumour size and normalised SI compared to PD (without controlling for body size in
the other submodels), plotted with 95% confidence intervals.
detection. We also include PD in the screening sensitivity function as a confounder,
since PD is negatively correlated to body size. The estimates point in the directions that
a high body size both delays the symptomatic detection and makes tumours grow faster.
The p-value for the joint association test (H0 : body size not associated with either
process, HA : body size associated with at least one of the processes) was 5.0 · 10−5.
Individually, only the association with symptomatic detectability reached statistical
significance (p-value=0.022 for symptomatic detection and p-value=0.089 for inverse
tumour growth rate).
6.3 Simulation-based studies
6.3.1 Detection of image markers related to screening sensitivity
In Study III, we compared the use of univariate logistic regression with interval vs.
screen-detected cancer as the dependent variable, to our continuous tumour growth
model setting (including a covariate in the screening sensitivity function), for detecting
image markers related to the masking of tumours (Section 5.6). Comparisons were made
on simulated data, which included a hypothetical image marker that affected screening
sensitivity. Results showed that the statistical power to detect markers related to
screening sensitivity was much larger for the continuous tumour growth model than it
was for the logistic regression model. This was true when simulating data under our
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continuous tumour growth model, using varying underlying speeds of growth, as well as
when simulating under a logistic tumour growth law.
6.3.2 Length-biased sampling and the effect of length bias on survival
comparisons
In Study IV we simulate data to study length-biased sampling and the effect of the bias
on survival comparisons between e.g. screening and interval cases. Under our proposed
continuous tumour growth model screening cases had longer tumour presence times (see
Section 5.6) than interval cases. This was (partly) caused by interval cases and screening
cases having different inverse tumour growth rate distributions – interval cases had on
average faster growth rates than screening cases. However, we could also demonstrate
another cause for the difference in tumour presence time distributions (which is seldom
discussed in the literature) – that interval and screening cases had different distributions
for symptomatic tumour size (the size at which a tumour would have been detected, in
absence of screening). In general, for a tumour to be screen-detected, it is required that
the tumour is not detectable by symptoms too early in the disease progression. As both the
symptomatic tumour size and the inverse tumour growth rate affect breast cancer specific
survival, both of these factors are a part of the length bias. Different conclusions can
be drawn from this. One being that it may not be correct to assume that the difference
between interval and screen-detected cases in tumour size distributions (in the presence
of screening) is a result of the stage shift. However, it is likely that a large proportion of
the difference is a cause of the earlier detection.
Regarding the effect of the length biased-sampling on survival comparisons between
interval and screen-detected cases, novel theoretical conclusions can be drawn based on
our model. Although it is likely that the length bias gives a survival advantage for screen-
detected cases in comparison to interval cases, there is a hypothetical chance that the
opposite is true. This can occur if the tumour growth rate does not affect survival to any
large extent, whilst tumour size at diagnosis does, and that there is a group of women
with a delayed symptomatic onset. In addition, a length bias correction procedure, to be
used on survival comparisons, should not only be based on tumour growth rate, but should
preferably also take symptomatic tumour size into account.
This is a simplified scenario; it is likely that the length bias is affected by other factors
as well, such as the complete tumour stage and biology.
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7 Discussion
Many of the results presented in this thesis are based on the assumptions of the same
underlying natural history model, including an exponential tumour growth with a gamma
distributed inverse tumour growth rate, a tumour volume-dependent hazard function for
time to symptomatic detection and a logistic function for mammography screening
sensitivity dependent on the tumour diameter. As is the case for all model assumptions
used for explaining complex real-life processes/events, the ones used in this thesis will
not be exact, but hopefully are approximate enough to be useful. It however seems
reasonable that results from different statistical models together provide stronger, more
robust evidence, than what can be provided from one model alone, as has been the line of
thought adopted by the CISNET consortium [63, 65].
The described natural history model was partly chosen for mathematical tractability –
with its use many processes may be derived and viewed as analytical expressions, on an
individual (conditional) level. In addition, analytical approaches for testing for
associations of covariates in all parts of the model can be developed. It is likely that a
simulation-based approach for calibration would have to be developed instead of an
analytical estimation procedure, if e.g. the exponential growth law, should be changed to
some more mathematically complex growth law. The reason being that many of the
analytical expressions used for estimation would not be possible to derive; for example
the distribution for tumour sizes at symptomatic detection in absence of screening.
Our model is not as complete in terms of the number of processes included/estimated,
as the models used in the CISNET consortium [63, 65]. It is however unique and has the
potential to be developed further. All of the CISNET models except one, are based on
simulation-based approaches for calibration. The one analytical approach [85] is based
on a (partly Markovian) multi-state model rather than a continuous tumour growth
model. However, our model does not differ in terms of the exponential tumour growth
law assumption, comparing it to the three models assuming a continuous tumour growth.
Regarding the CISNET models, an interesting note is that the MISCAN-Fadia model
described by Tan et al. [110] is based on a continuous exponential tumour growth model,
but was originally developed as the MISCAN model, a discrete state progression model
presented in for example Habbema et al. [130]. The transition in models was made to
improve the description of biological mechanisms, by the inclusion of a continuous
tumour size. It was also made to enable a separation of processes of tumour growth, and
clinical and screen detection.
Natural history model estimates differ in published studies, depending on both the data
utilised, but also the statistical modelling and estimation techniques used. Not all of the
quantifications in this thesis can be compared to other estimates. This is especially true
for the quantifications of BMI on growth rate (Study II), TBA on symptomatic detection
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(Study II) and SI on mammography screening sensitivity (Study III), as these are to the
best of my knowledge, the first of their kind. However, BMI was estimated to be an
inverse promoter of clinical disease, using a multi-state Markov model setting, in a study
by Yen et al. [83]. As previously mentioned, the reason for a variable to be a promoter
can differ. A variable may be an inverse promoter if it has either a slow growth rate,
or a delayed symptomatic detection, or an earlier possibility of screen-detection. For
body size, the two latter processes have been hypothesised (due to the correlation with
PD). This result is however in line with our finding that there is a higher evidence for
a delayed symptomatic detection in comparison with a faster tumour growth for women
with higher BMI. However, in general, as multi-state models do not separate time into
growth rate and symptomatic detectability, they are not well suited for explaining reasons
behind associations between covariates and tumour size.
Our estimates of the role of tumour size in mammography screening sensitivity differ
to some extent from the ones presented by Tan et al. [89]. They used a 13-state Markov
model with tumour size categories (diameter in mm) of ≤ 10, 11− 20, 21− 50 and ≥
51 and estimated corresponding screening sensitivities of 90, 91, 92 and 93% (in DCIS
tumours the sensitivity was estimated to be 88%). Our results suggest that tumour size
plays a more important role for screening sensitivity. It is likely that estimates vary due to
the different statistical models used, but also due to the large tumour size intervals used
by Tan et al [89]. It would have been interesting to see their quantification of sensitivity
for tumours with a diameter of ≤ 5 mm. In comparison to the studies by Weedon-Fekjær
et al. [92, 106], which assumed the same parametrical model for screening sensitivity, our
estimate lies in between their two published ones.
There are fewer comparisons to make regarding our estimate of the role of PD in
mammography screening sensitivity, especially when also considering tumour size. In
2004, Berg et al. [70] quantified screening sensitivity for the BI-RADS categories, but
without taking tumour size into account. They estimated a 60% sensitivity in extremely
dense breasts and a 100% sensitivity in predominantly fatty breasts. However, their
sample size was small (110 breast cancer cases). Based on the three-state basic Markov
model, Chiu et al. [131] reported a sensitivity of 62.8% in dense breasts (Tabár patterns
IV and V) and a sensitivity of 82.0% in non-dense breasts (Tabár patterns I-III).
Estimation of screening sensitivity and mean sojourn time was however not performed
jointly. More common in multi-state Markov models is to estimate age-specific
sensitivities [85, 132], which are not directly comparable to our estimates.
According to the quantification of tumour growth presented in Section 6.2, the median
doubling time in days is estimated to be 105 days. Weedon-Fekjær et al. [92, 106]
presented median doubling times of 99 and 152 days for tumours at 15 mm, assuming a
logistic growth law. This growth law however leads to shorter doubling times for smaller
tumours and longer doubling times for larger tumours. Corresponding estimates of the
mean sojourn time from multi-state Markov models also tend to vary between studies
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and data sets [90, 133, 134]. These are, as discussed, not directly comparable to our
estimates of growth rate. However, they may be used as reference values for mean lead
times (lead times follow the same distribution as sojourn times in memoryless Markov
models). Our estimate of the length of lead times is shorter than many estimates of the
mean sojourn times, but in line with the shorter quantifications presented. Our lead time
estimate also resembles the estimate of mean lead time being close to one year, presented
by Chen et al. [135] (but not, for example, the four years adopted by Duffy et al. [96] in
their average lead time correction procedure).
Using a similar continuous tumour growth model, but for data in absence of screening
and with the constraint that the expected inverse tumour growth rate is equal to one,
Plevritis et al. [87] estimated that symptomatic detection occurred later in the disease
progression than what is suggested by our estimates. Our model claims that tumours
growing with a median growth rate are not usually symptomatically detected after a
tumour size of 40 mm, in comparison to 60 mm, based on their parameter estimates. The
difference in estimates may be caused by both differences in model assumptions (fixing
the mean inverse tumour growth rate to one, or not) as well as non-exchangeable data
sets. Breast cancer cases were diagnosed between 1975 and 1981 in the study presented
by Plevritis et al. [87] whereas women in CAHRES were diagnosed between 1993 and
1995.
One of the potentials with the proposed continuous tumour growth model is its ability
to shed further light on traditional concepts, such as the length bias. In Figure 7.1 the
length biased-sampling is depicted as being caused by the rate of tumour growth and
symptomatic tumour size, to be compared with Figure 2.10 in which only the dimension
of (sojourn) time has been plotted. In Figure 7.1 the screen-detected case has a longer
tumour presence time than the two depicted interval cases, although the reasons behind
this differ; one of the interval cases grows faster but has the same symptomatic tumour
size as the screen-detected case, the other interval case is easy-detectable but grows with
the same speed as the screen-detectable case.
For practical reasons (including computational times) it was unfortunately not possible
to present updated parameter estimates using the probability (5.16) in the conditional
probability for tumour size (5.14), for results presented in Studies I and II. However, the
parameter estimates of Study III are similar to the published estimates in Study I. It seems
reasonable that the estimates in Study II would not change much either. In any future
study of the role of body size for growth rate and symptomatic detectability, it would
be interesting to also include, for instance, HRT as a confounder. This would now be
practically possible in our continuous tumour growth model setting as the computational
times have been improved upon [129].
Breast cancer is a heterogeneous disease. The natural history model presented herein
is simplistic, but can be used to form the basis of a novel statistical model. To be of
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Figure 7.1: An illustration of length biased-sampling in two dimensions, where
the time the tumour is present in a woman’s body depends on the tumour growth
rate and symptomatic detectability. The crosses represent times for detection. The
screen-detected case has a slow growth rate and a delayed symptomatic detection.
higher relevance for future research it should be developed further. There are however
unlimited expansions possible for the model in terms of including a complete tumour
stage (with a possibility for tumours to stagnate in progression), a submodel for tumour
onset and also one for breast cancer specific survival. Analytical expressions for all these
processes are however challenging to derive, but once done, use of covariates within these
processes may provide a comprehensive picture of the natural history of breast cancer.
Such a model can be used for different purposes, for example to evaluate benefits and
harms from screening programmes, either by using simulation studies or by estimating
effects directly from observational data. The model can also be used for jointly testing for
associations between risk factors/covariates in different latent processes.
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8 Concluding remarks
In this thesis the basis of a novel natural history model for data on breast cancer cases in
presence of mammography screening, has been described. The model is called a
continuous tumour growth model and makes it possible to jointly estimate latent
continuous processes of breast cancer tumour growth, time to symptomatic detection and
mammography screening sensitivity. All parts of the model have the possibility of
including covariates. In comparison to multi-state models, it has the advantage that it
divides sojourn time/transition rates from preclinical to clinical disease, into processes of
tumour growth rate and time to symptomatic detection. This enables further
understanding of the natural history of breast cancer and e.g. increases knowledge of
reasons behind covariates being promoters of clinical disease. Also, the model is
superior in statistical power for detecting image markers related to masking of tumours,
compared to univariate logistic regression with detection mode (interval vs.
screen-detection) as the dependent variable.
The model framework makes it possible to derive individual (conditional)
distributions of latent variables, rather than distributions on a population level
(unconditional), an example being the lead time. The conditional lead time distributions
derived in this thesis suggest that especially tumour size at screen diagnosis is of great
importance for predicting when symptomatic detection would have occurred in absence
of screening. We have shown how the conditional lead time distributions derived in this
thesis can be used for correction of the lead time bias in survival comparisons between
for example screen-detected and symptomatically detected cases. The conditional
distributions are especially useful in stratified analyses. For the length bias, according to
our continuous tumour growth model, the time a tumour is present in a woman’s body is
dependent on the tumour growth rate, but also the symptomatic tumour size. The latter is
not usually discussed in the literature describing this bias. Since tumour growth rate and
tumour size have their own relationships with survival, a length bias correction including
both parts is superior to one being based on sojourn time. The extended view of this bias
is also of importance for some interpretations of analyses affected by the length bias.
In applied work on postmenopausal breast cancer cases, we could quantify the
relationship between tumour size and the probability that a tumour will be detected at
screening. We could also show that percentage mammographic density, a quantitative
image marker of mammographic density, significantly improves predictions of
sensitivity. The image marker however does not take into account how the dense tissues
are distributed in the breast. A measure of the scatteredness of dense tissues, referred to
here as skewness of the intensity gradient, may have a higher ability than percentage
mammographic density to distinguish between which women that have high or low
mammography screening sensitivity.
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Women with larger body size have an increased mammography screening sensitivity
(due to having a lower percentage mammographic density), still their tumour sizes at
diagnosis are larger. We could conclude that this is (partly) caused by women with larger
breasts having difficulties in symptomatically detecting their tumours, or alternatively,
delaying their visits to health care. Although not statistically significant, our results point
in the direction that this is also caused by a faster tumour growth rate for women with
higher BMI.
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9 Future perspectives
Nowadays breast cancer screening programmes (with some exceptions) invite all women
within a specific age range to be screened with the same frequency. It is becoming clear,
however, that this may not be the best use of health care resources. Researchers are
discussing how screening programmes could be implemented on a more individualised
level [136]. Overall (long-term) breast cancer risk for a woman is probably the major
factor that could be useful in deciding which women that should be screened and how
often, but other factors (risk of particular subtypes), body size, may also be important.
Implementation of individualised programmes could indeed improve the balance of
benefits and harms from screening that women encounter, but pragmatically could be
difficult or costly to implement.
Studying the processes discussed in this thesis, of screening sensitivity, symptomatic
detectability and tumour growth, may shed light on issues around individualising
screening programmes even further. The following is a simplified discussion of these
processes and how knowledge about them could be useful for thinking about
individualised screening.
For a screening programme to be efficient, and balance benefits and harms, women
with a high enough risk of dying from breast cancer should clearly be screened. For each
woman attaining such risk level, screening with a tool having a high sensitivity needs to
be offered. As use of mammography screening is the golden standard in today’s health
care, individual quantifications of mammography screening sensitivity may be able to
point out (probably together with analyses of cost-effectiveness) which women that
should be offered another type of screening modality to increase sensitivity. Use of
image analysis and rich data sources including mammograms, can help in further
distinguishing screening sensitivities between (and within over time) individuals, as
exemplified in Study III using the scatteredness of mammographically dense tissues to
explain screening sensitivity, rather than the fraction of mammographically dense tissues
in the breasts.
To some extent, for women not expected to die from other causes any time soon, the
risk of dying from breast cancer in absence of screening, can be explained by processes
of tumour growth rate and symptomatic detectability. However, other factors of tumour
heterogeneity that are linked to the choice of treatment, such as molecular subtypes, are
of great importance. These will not be included in this short and simplified discussion,
as they have not, as of yet, been studied in this continuous tumour growth model. Other
factors considered, fast growing tumours may, on average, have worse prognosis than
slow-growing tumours. Fast growing tumours also have shorter windows of opportunity
for being screen-detected. Individual quantifications of risk of getting fast-growing breast
cancer, may help in distinguishing which women should be screened with short intervals.
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Even then, screening may not be well-suited to fast-growing cancers. Therefore, if the
risk of such cancer is high, preventive actions may also be of importance. In women with
risk of only slow-growing breast cancer, a less frequent screening programme may be
useful. If in addition such a woman has a high chance of early symptom onset (i.e. of
finding the tumour by symptoms whilst it is still small) she may not need to participate in
screening. For example, this may be the case for women with very small breasts. For all
women, having a risk of delayed symptomatic onset and of getting fast or slow-growing
breast cancer, screening is probably a useful tool.
In a recent study by Cohen et al. [137] a novel blood test called CancerSEEK, which
can be used for screening eight different cancers, was proposed. The blood test was taken
on cases having different types of cancer. For some cancer types, the sensitivity was
high, but for breast cancer it was only 33%. However, in a future individual screening
programme of breast cancer, a similar but improved blood test could potentially be of use
as a complement to other screening modalities.
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